• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

10.01.2025
Dollar Strength Is a Given

The very first slice of statistical data on business activity from the United States this year reaffirmed an almost clear irrelevance and even potential hurtfulness of any immediate steps towards further lowering interest rates on U.S. Dollar-nominated loans from a purely economic point of view. The ISM Manufacturing PMI (Purchasing Managers Index), based on polls compiled from executives in over 400 industrial companies in late December, came out at 49.3 points vs 48.4 a month ago and 48.2 in average analyst estimates. This showed that a slowdown was occurring at a slower or even insignificant pace, keeping inflation risks on the table, especially when the price component increased from 50.3 to 52.5 with a similar rate of increase in new orders. Meanwhile, non-manufacturing PMI came out at 54.1 on Tuesday, compared to 53.5 in analyst polls and 52.1 a month ago, with a contribution of business activity components even jumped to a surprising 58.2 against declining from 57.2 in November to only 53.7 in December.

In other words, the economy is not cooling, and is rather in a positive acceleration, which in turn may lead to a recovery in wage rises and therefore to higher demand pressure, which may be reflected soon in higher producer purchase and output prices. Doubts of the major U.S. financial regulator are understandable at this point after its triple rate cut from 5.5% to 4.5% in 2024. The Federal Reserve (Fed) will now pay closer attention not only to consumer inflation measures, but also to producer prices (PPI), which is just going to be released on coming Tuesday, January 14. And so, this will become the next reference point in the further U.S. Dollar’s trajectory. The Greenback index (DX) is picking up steam since reaching a new record high for the last two years at 109.35, with its temporary pullbacks being limited by a 107.50 support area that previously served as a strong multi-month technical resistance.

In this context, the British Pound (GBPUSD) updated its lows since November 2023 to touch 1.2237 on January 9, EURUSD feels quite comfortable within a range between 1.02 and 1.0450, which corresponds to its 2-year bottom, and having a bias towards a possible further decline. The Aussie (AUDUSD) is one-step away from taking the path for a breakthrough to a quite unknown territory of its 5-year lows that were last time recorded when the initial outbreak of the Covid-19 happened.

A varying extent of the American Dollar strength is surely data dependent as the market community is eagerly waiting for the U.S. job data later today. The average expectations on new Nonfarm Payrolls is just a bit above 150,000 vs 227,000 in early December 2024 and nearly 160,000 for the previous four months on average. However, any value close to 150,000, plus or minus 20,000, or any higher number, may be considered as another positive sign for the Greenback, following the ADP national employment report which contained only 122,000 on Wednesday. The oppressive nature of average hourly wage in its dynamics, +0.4% each time from September to December, also matters.

The protective quality of investing more funds into the U.S. Dollar and U.S. bonds against tariff threats is switched on anyway, based on more than a 95% chance for the Fed to keep rates on pause at its January 29 meeting, according to CME's FedWatch tool. Federal Reserve officials never go against a well-established market consensus, when it is almost unanimous, for not to rock the boat of relative market trend stability. The central bankers' reluctance to shift the Fed fund rates lower before mid-March, if not early May, continues to play in favour of short-term speculative transactions on the foreign exchange market, bearing in mind all the listed currency instruments. Some intraday volatility may take place, especially in the case of appearing an abnormal two-digit non-farm value, but not a change in overall direction.

Rafael Quintana Martinez
Money Manager de alto rendimiento, con una sólida formación académica, profesional y de campo. Más de 9 años de experiencia especializada en el comercio de mercados financieros internacionales. La devoción, la fiabilidad, la responsabilidad y la ética impulsan mi vida. Actualmente me desempeño como Analista Senior para Metadoro. https://metadoro.com/es https://mx.investing.com/members/contributors/235587671/ https://es.tradingview.com/chart/EURUSD/rE9gVips/
LRC is Struggling to Recover Towards $0.300

Loopring (LRC) saw a decline of 1.6% this week, trading at $0.248. This movement can be interpreted as a consolidation phase following a significant 39% drop over the weekend, which occurred amidst heightened military tensions in the Middle East. Despite the consolidation, prices are currently below the support of an ascending channel that has remained intact since October 20, 2023.

For the fifth consecutive day, the altcoin has been closing below this critical support level. To resume its upward trajectory, LRC would need to stage a recovery of at least 50%, reaching $0.300. While such a recovery is plausible, any further delays in reclaiming this level could lead to a deterioration in prices, potentially pushing LRC below $0.200.

Such a scenario would be detrimental for the altcoin, as it would signify a breakdown from its established channel and could trigger significant selling pressure.

2244
The Best Performing US Bank in the Earnings Week: Morgan Stanley

Morgan Stanley (MS) is one of the best performers among the largely drowning stocks of US banks during this earnings season. Indeed, it managed to hold nearly 2.5% of intraday gains at the regular session of April 16, when its Q1 report came out. Yet, the initial surge in share price reached a 4% of height soon after the opening bell, accompanied by fresh profit taking, as no enthusiastic buyers were seen near these slightly elevated levels. Technically, the two latest candlesticks on MS daily charts turned black despite initial price gaps, which is not a positive sign even for the short-term.

A chance for testing multi-month resistance at nearly $95 per share is still here, because Morgan Stanley showed no essential weaknesses in its own forecasts for the rest of the year, unlike other monster financial institutions including JPMorgan Chase and Wells Fargo, which noted last Friday that their interest payments were below expectations, as the whole banking industry needed to be ready to future Federal Reserve's rate cuts. Rising uncertainty over the central bank's outlook for the borrowing costs prompted the benchmark 10-year public bond yields to soar above 4.65% this week, which is good for interest income, but understates the value of the banking balance sheets, based on the same kind of U.S. bonds which the banks had to acquire for safe haven purposes over the years. Now these bonds rather became the source of financial rigidity, or one may call it awkwardness, leading to the lack of free cash the banks may use for their lending business and investment purposes.

As other Wall Street banking pillars, Morgan Stanley beats consensus estimates in terms of its incredible past performance. Higher investment banking segment helped a lot, which also took place in the case of Goldman Sachs, as another rather positive example. "We saw building momentum in investment banking, both in our M&A and underwriting pipelines across corporate and financial sponsor clients," Morgan Stanley CEO Ted Pick commented, adding that a "multi-year M&A cycle" is to be launched now, and this period may last 3 to 5 years. Geopolitical risks may even create incentive for more deals, he said, when businesses are shifting their international footprint partly because of the two major conflicts. Morgan Stanley also noted it is still bullish on the U.S. economy.

Q1 2024 was the best quarter for MS since April 2022, as the banking group announced its EPS (equity per share) of $2.02 vs consensus estimates of $1.66. A more than 20% surplus compared to average forecasts, yet a rising wave on charts is very modest. Logically, the situation around other banking stocks with worse reported (and especially forecasted) numbers may be even less enjoyable for the bullish camp. We clearly understand that other large banks are usually more dependent on their customers' well-being, rather than investment projects. This is why the Bank of America lost 3.5% on the same day, despite its EPS was also more than 9% above consensus estimates, yet this has not bailed it out to escape from price falling. Competition in high yield from private credit and leveraged loan markets were marked even in the conference call by Morgan Stanley.

The first quarter was good for most U.S. banks, yet the future prospects scared the crowds of investors. If so, they are ready to move down on the stocks of many other big banks and are ready to be no more than just patient in the best cases like Morgan Stanley and Goldman Sachs. There is a great distance between the road of tolerance to potential headwinds and the road of enthusiastic buying on the hot heels of earnings reports. So, other segments seem preferable compared to any banking stocks.

2549
Johnson & Johnson Failed To Reverse the Downtrend

Johnson and Johnson (JNJ) was the first member of the health consumer staples club to report in the spring on Wall Street. As a large producer of essential hygiene products, personal care items and services, it could reap the benefits of its unique positioning on markets as most people are addictive in their nature to the same kind of skin health brands and baby medications. JNJ is also one of the world leaders in providing prescription and over-the-counter drugs, surgical equipment and orthopaedic implants, which are difficult to be replaced by anything else. Nevertheless, the stock lost 2.15% of their value on April 16. As a result, a smoothly descending channel on monthly charts since the beginning of 2023 still stands intact.

Nominally, the Q1 growth numbers were even better than expected, with EPS (equity per share) coming out at $2.71 vs $2.64 of consensus projections. Yet, there is almost no increase in profit in absolute terms over the past two years, which means the medtech giant is earning less if adjusted for inflation effects. Therefore, even though J&J performance in the segment of innovative medicine could be called impressive, as it contributed to 63.5% of the company's sales amounting to $13.56 billion against preliminary estimates of $13.47 billion, most large investment houses were not satisfied. Some of them just preferred to moderately cut their mid-term targets for the company's price, in the range of $5 to $10 per share to the current levels around $145, citing a lacklustre in forward guidance parameters for the rest of 2024, foreign exchange headwinds (a reason why international sales declined by 0.3% Y0Y) and other factors like a potential loss of exclusivity for Stelara drug brand, which was designed to treat psoriasis, related arthritis and ulcerative colitis.

Johnson & Johnson sees its adjusted operational EPS to range between $10.60 and $10.75 for 2024, with "Innovative Medicine sales growth is expected to be stronger in the first half of the year". Does it mean that the second part of 2024 would experience a slowdown? Again, the Vision Care business of the giant has narrowed due to "changes in distributor inventory". JNJ's CEOs commented on the strategic acquisition of Shockwave Medical and Ambrx to strengthen the company's cardiovascular and oncology portfolios, which could be important but still questionable from the point of view of future financial return. The session of questions and answers during the conference call also included the multiple myeloma franchises and litigation related to some patents, while the company's representatives affirmed confidence in their solid position. The company's future prospect looks rather optimistic, yet the share price dynamics based on mentioned challenges suggests that prematurely buying of JNJ stock at any levels well above the lows of April 2020 may be unreasonable, if only no fresh fundamental drivers appear.

2311
B
The Rally Will Remain Safe and Sound

I don't think the recent S&P 500 retracement to a 5,050-5,075 area is threatening the stock rally. This short correction began last Friday only because of the clear drawdown in the US banking segment. I expected the trash scenario for the flagship banking stocks when I sold off my last remaining stocks of JPMorgan (JPM) just a day before the bearish signs were included into its weaker forward guidance as an attachment to a regular and strong quarterly report. I am not going to repeat all of my arguments behind the situation. Anyway, when other sectors of the market are mostly stable or unmoved, the downward momentum by several leading banks define the overall bearish mood for the broad indexes. Meanwhile, the fundamentals of the rally, especially in the AI and e-commerce segments, still look as strong as it was a couple of weeks ago and in recent months as well. Therefore, I feel comfortable to invest some free cash into temporarily discounted chip producers like AMD, or into the GPT chats based giants, including Microsoft and Google. I have no doubts in a step-by-step recovery of AMD from its current $160 per share to above $200 once again to cover a nearly 30% discount from its peaking price, even though high bond yields behind a drop in banking stocks, Middle East developments to some extent, may bring the S&P 500 to 5,000 or even a little bit lower when going with the flow. All this temporary agenda is hardly to change the basic instincts of large investment houses that avoid money and want more shares in growing businesses.

2917
130

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors